Cover Image

PAPERBACK
$43.50



View/Hide Left Panel

Pathogen

Vaccine Envisaged

Target Populationa

Respiratory syncytial virus

Polypeptides produced by recombinant DNA technology

Infants at earliest possible age

 

Attenuated live virus

Infants at earliest possible age

Rotavirus

Attenuated high passage bovine RV

Infants at earliest possible age (preferably with oral polio vaccine)

 

Attenuated low passage bovine RV

Infants at earliest possible age (preferably with oral polio vaccine)

 

Rhesus monkey RV

Infants at earliest possible age (preferably with oral polio vaccine)

Salmonella typhi

Attenuated ga1E mutant S. typhi strain TY21a

Children; young adults at risk; travelers from developed countries to endemic areas

 

Aromatic amino acid dependent strains of S. typhi

Children; young adults at risk; travelers from developed countries to endemic areas

Shigella spp.

Probably plasmid mediated outer membrane protein invasion determinant (there are a small number of promising options needing investigation to determine best approach)

Infants at birth or earliest possible age; elderly for epidemic strains

Streptococcus A

Synthetic M protein segment (excluding portions cross-reacting with human tissue)

Children, <3–4 yrs

Streptococcus pneumoniae

Conjugated polysaccharides, polyvalent

Infants

Vibrio cholera

Genetically defined live mutant V. cholerae (A−B+ or A−B−) with respect to toxin subunit synthesis

Children, esp. <2 yrs

 

Inactivated antigens

Children, esp. <2 yrs

Yellow fever virus

Attenuated live virus produced in cell culture

Young children

aCalculations of benefits are conducted assuming delivery at ages consistent with schedules of vaccinations recommended by the World Health Organization Expanded Program on Immunization (see Chapters 6 and 7).

development in the coming decade. The vaccine-disease combinations to be described in the supplement should be regularly reviewed for possible inclusion in future applications of the model.

DETERMINATION OF HEALTH BENEFITS

To compare diseases and vaccines, it was necessary to develop a system that would allow expression of the total morbidity and mortality



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement